Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes at EASD 2024
Shots:
- The P-III (QWINT-2 & 5) studies assessed efsitora vs degludec in T2D patients (n=928) using/not using GLP-1 agonist and T1D patients (n=692) on daily basal & multiple daily mealtime insulin, respectively, for 52wks.
- QWINT-2 reached its 1EP at wk.52, showing non-inferior A1C reduction (resulting A1C) of 1.34% (6.87%) vs 1.26% (6.95%); 1.30% (6.90%) vs 1.28% (6.92%) in those using GLP-1s & 1.38% (6.85%) vs 1.23% (6.99%) in those not using GLP-1s; subjects spent 45mins. more time in range. Results published in the NEJM
- QWINT-5 reached its 1EP at wk.26, showing non-inferior A1C reduction (resulting A1C) of 0.53% (7.37%) vs 0.59% (7.32%). Time in range during the 4wks. before wk.26 was 52.8% vs 53.1%. Results published in the Lancet
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.